Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab
Journal of Cutaneous Medicine and Surgery · 2023
DOI: 10.1177/12034754231167140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Medicine and Surgery, 2023. Verfasst von Adel Alsenaid und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Psoriasis, Eczema, Biological Products. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Biological treatments targeting IL-17 are highly efficacious with rapid onset of action in psoriasis. Cutaneous adverse events are associated with different biological treatments, including paradoxical psoriasis and eczematous reactions. Brodalumab was previously suggested as an alternative treatment option in psoriasis patients who developed dermatitis or paradoxical psoriasis while on a biologic. Here we report three psoriasis patients who developed brodalumab induced eczematous reaction with complete clearance after switching to risankizumab. Early recognition is crucial for appropriate management. We propose switching patients with psoriasis who develop severe eczematous reaction while on a biologic targeting IL-17 to an IL 23 inhibitor due to efficacy in psoriasis and rarely reported eczematous reaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada.
- Division of Dermatology, College of Medicine, Shaqra University, Dawadmi, Saudi Arabia.
- Division of Dermatology, Women's College Hospital, Toronto, ON, Canada.
- Division of Dermatology, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
- Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
ORCID-Profile: Adel Alsenaid, Vincent Piguet, Marissa Joseph
Zitieren
APA
Alsenaid, A., Piguet, V., Lansang, P., Miller-Monthrope, Y., Yeung, J., & Joseph, M. (2023). Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/12034754231167140
Vancouver
Alsenaid A, Piguet V, Lansang P, Miller-Monthrope Y, Yeung J, Joseph M. Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab. Journal of Cutaneous Medicine and Surgery. 2023. doi:10.1177/12034754231167140
BibTeX
@article{Alsenaid2023,
author = {Alsenaid, Adel and Piguet, Vincent and Lansang, Perla and Miller-Monthrope, Yvette and Yeung, Jensen and Joseph, Marissa},
title = {Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab},
journal = {Journal of Cutaneous Medicine and Surgery},
year = {2023},
doi = {10.1177/12034754231167140}
}
EUVIMED